Biomarker discovery and validation
8 European H2020 organizations list this as part of their work — 5 as their primary capability.
Most active in this area
- PFIZER LIMITED
Global pharmaceutical company contributing drug development expertise, clinical data, and regulatory science across 54 H2020 health research partnerships.
“Core contributor across BIOMAP (atopic dermatitis/psoriasis biomarkers), LITMUS (liver biomarkers), TransBioLine (safety biomarkers), IB4SD-TRISTAN (imaging biomarkers), and MOBILISE-D (digital biomarkers).”
PrimaryUK54 projects - LUXEMBOURG INSTITUTE OF HEALTH
Luxembourg biomedical research institute specializing in biomarker discovery, cancer immunoprofiling, and translational diagnostics across major disease areas.
“Central to projects LITMUS (liver biomarkers), COVIRNA (COVID-19 RNA biomarkers), IMMUcan (cancer immunoprofiling), EPND (neurodegenerative biomarkers), MITO (hypertension microRNA), and SPIDIA4P (pre-analytical standardization).”
PrimaryLU24 projects - ANAXOMICS BIOTECH SL
Barcelona SME providing systems biology and network medicine modeling for biomarker discovery, personalized medicine, and drug mechanism analysis across multiple disease areas.
“Biomarker identification is a recurring deliverable across DRIVE, SECRET, proEVLifeCycle, SMA-TB, RECOGNISED, and LIVERHOPE.”
PrimarySMEES12 projects - LGC LIMITED
UK measurement science company providing standardized genomics, biomarker validation, and ISO-quality analytical services to European health research consortia.
“MIRIADE involved protein bioinformatics, data integration, and clinical validation of novel protein detection methods for dementia diagnosis.”
UK4 projects - KOMPETENZNETZ VORHOFFLIMMERN E.V.
German clinical research network specializing in atrial fibrillation, stroke prevention, and AI-powered cardiac diagnostic platforms.
“Biomarker research features in both CATCH ME (disease mechanisms) and AFFECT-EU (risk stratification).”
DE3 projects - MICROPATHOLOGY LIMITED
UK diagnostics SME specializing in molecular detection and RNA-based personalised diagnosis of infectious and febrile diseases.
“PERFORM explored biomarkers for distinguishing bacterial vs viral infection, and DIAMONDS builds on this with RNA molecular signatures.”
SMEUK3 projects - ACOBIOM
French biotech SME specializing in biomarker discovery and in vitro diagnostic development for cancer, psychiatric, and infectious diseases.
“All three H2020 projects (R-LiNK, LeiSHield-MATI, ImOPac) involve biomarker identification across different diseases.”
PrimarySMEFR3 projects - China Capital Medical University
Beijing clinical university offering Chinese hospital access and biomarker expertise for brain disease and cancer diagnostic research consortia.
“Both BBDiag and AiPBAND involve biomarker-based diagnostic development, with AiPBAND explicitly listing biomarker discovery and validation as core keywords.”
PrimaryCN2 projects